title: Congress responds to the IOM drug safety report--in full.
authors.affiliation: Cardiovascular Health Research Unit, Department of Medicine, University of Washington, and Center for Health Studies, Group Health Cooperative, Seattle, WA 98101, USA. psaty@u.washington.edu
authors.forename: Bruce M
authors.initials: BM
authors.lastname: Psaty
authors.forename: David
authors.initials: D
authors.lastname: Korn
mesh_terms: D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence / Q000592:standards*; D016265:Conflict of Interest; D016208:Databases, Factual; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D064420:Drug-Related Side Effects and Adverse Reactions; D015969:National Academies of Science, Engineering, and Medicine, U.S., Health and Medicine Division; D011057:Politics; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration